Rakan Alqahtani

Dr. Rakan Alqahtani


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Trials
Verified
Journal Article
Open access
PDF file
YAYaseen M Arabi
Yaseen M Arabi
SASara Aldekhyl
Sara Aldekhyl
SQSaad Al Qahtani
Saad Al Qahtani
HAHasan M Al-Dorzi
Hasan M Al-Dorzi
SASheryl Ann Abdukahil
Sheryl Ann Abdukahil
HTHaytham Tlayjeh
Haytham Tlayjeh
Background: Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation has multiple advantages over other oxygen support modalities but data about effectiveness are limited.Methods: In this multicenter randomized trial of helmet noninvasive ventilation for COVID-19 patients, 320 adult ICU patients (aged ≥14 years or as per local standards) with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (ratio of arterial oxygen partial pressure to fraction of inspired oxygen < 200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate of 10 L/min or higher) will be randomized to helmet noninvasive ventilation with usual care or usual care alone, which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction in 28-day mortality from 40 to 25%. The primary outcome will be compared between the helmet and usual care group in the intention-to-treat using the chi-square test. Results will be reported as relative risk and 95% confidence interval. The first patient was enrolled on February 8, 2021. As of August 1, 2021, 252 patients have been enrolled from 7 centers in Saudi Arabia and Kuwait.Discussion: We developed a detailed statistical analysis plan to guide the analysis of the Helmet-COVID trial, which is expected to conclude enrollment in November 2021.Trial registration: ClinicalTrials.gov NCT04477668. Registered on July 20, 2020

2 March 2021 in Environmental Science and Pollution Research
Verified
Journal Article
Open access
PDF file
MAMarwa Adel Afify
Marwa Adel Afify
RARakan Alqahtani
Rakan Alqahtani
MAMohammed Abdulrahman Mohammed Alzamil
Mohammed Abdulrahman Mohammed Alzamil
FKFatin Khorshid
Fatin Khorshid
SASumayyah Mohammad Almarshedy
Sumayyah Mohammad Almarshedy
MAMohammad Almohideb
Mohammad Almohideb
We conducted the current analysis to determine the potential role of polio vaccination in the context of the spread of COVID-19. Data were extracted from the World Health Organization’s (WHO) Global Health Observatory data repository regarding the polio immunization coverage estimates and correlated to the overall morbidity and mortality for COVID-19 among different countries. Data were analyzed using R software version 4.0.2. Mean and standard deviation were used to represent continuous variables while we used frequencies and percentages to represent categorical variables. The Kruskal-Wallis H test was used for continuous variables since they were not normally distributed. Moreover, the Spearman rank correlation coefficient (rho) was used to determine the relationship between different variables. There was a significantly positive correlation between the vaccine coverage (%) and both of total cases per one million populations (rho = 0.37; p-value < 0.001) and deaths per one million populations (rho = 0.30; p-value < 0.001). Moreover, there was a significant correlation between different income groups and each of vaccine coverage (%) (rho = 0.71; p-value < 0.001), total cases per one million populations (rho = 0.50; p-value < 0.001), and deaths per one million populations (rho = 0.39; p-value < 0.001). All claims regarding the possible protective effect of Polio vaccination do not have any support when analyzing the related data. Polio vaccination efforts should be limited to eradicate the disease from endemic countries; however, there is no evidence to support the immunization with live-attenuated vaccines for the protection against COVID-19.

29 June 2021 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
RARaed Ibrahim Altulayhi
Raed Ibrahim Altulayhi
RARakan Alqahtani
Rakan Alqahtani
RAReem Abdullah Alakeel
Reem Abdullah Alakeel
FKFatin Khorshid
Fatin Khorshid
RARehab Hamoud Alshammari
Rehab Hamoud Alshammari
MAMohammad Almohideb
Mohammad Almohideb

5 June 2021 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
MAMarwa Adel Afify
Marwa Adel Afify
RARakan Alqahtani
Rakan Alqahtani
MAMohammed Abdulrahman Mohammed Alzamil
Mohammed Abdulrahman Mohammed Alzamil
FKFatin Khorshid
Fatin Khorshid
SASumayyah Mohammad Almarshedy
Sumayyah Mohammad Almarshedy
MAMohammad Almohideb
Mohammad Almohideb

11 November 2022 in medRxiv
Verified
Preprint
Open access
PDF file
YAYaseen M Arabi
Yaseen M Arabi
HAHasan M Al-Dorzi
Hasan M Al-Dorzi
MSMusharaf Sadat
Musharaf Sadat
DMDina Muharib
Dina Muharib
HAHaifa Algethamy
Haifa Algethamy
TGthe Saudi Critical Care Trials Group
the Saudi Critical Care Trials Group
Background Protein intake is recommended in critically ill patients to mitigate the negative effects of critical illness-induced catabolism and muscle wasting. However, the optimal dose of enteral protein remains unknown. We hypothesize that supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge or ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day) would reduce all-cause 90-day mortality in adult critically ill mechanically ventilated patients. Methods The REPLENISH (Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial is an open-label, multicenter randomized clinical trial. Patients will be randomized to the Supplemental protein group or the Control group. Patients in both groups will receive the primary enteral formula as per the treating team, which includes a maximum protein 1.2 g/kg/day. The Supplemental protein group will receive, in addition, supplemental protein at 1.2 g/kg/day starting the fifth ICU day. The Control group will receive the primary formula without supplemental protein. The primary outcome is 90-day all-cause mortality. Other outcomes include functional and quality of life assessments at 90 days. The trial will enroll 2502 patients. Discussion The study has been initiated in September 2021. Interim analysis is planned at one third and two thirds of the target sample size. The study is expected to be completed by the end of 2024 Trial Registration ClinicalTrials.gov Identifier: NCT04475666. Registered on July 17, 2020 https://clinicaltrials.gov/ct2/show/NCT04475666